Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: Reversing tumor-induced defects
- 31 August 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Immunology
- Vol. 140 (2), 184-195
- https://doi.org/10.1016/j.clim.2011.04.017
Abstract
No abstract availableKeywords
This publication has 130 references indexed in Scilit:
- Targeting iNKT cells for the treatment of sickle cell diseaseClinical Immunology, 2011
- Harnessing natural killer T (NKT) cells in human myeloma: Progress and challengesClinical Immunology, 2011
- Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humansClinical Immunology, 2011
- Cytokine dependent and independent iNKT cell activationCytokine, 2010
- NKT cells, Treg, and their interactions in bone marrow transplantationEuropean Journal of Immunology, 2010
- Innate-like recognition of microbes by invariant natural killer T cellsCurrent Opinion in Immunology, 2009
- Cross‐regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigensJournal of Cellular Physiology, 2008
- CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune systemCurrent Opinion in Immunology, 2008
- Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR α‐chain CDR3 loopEuropean Journal of Immunology, 2008
- Peripheral blood IFN‐γ‐secreting Vα24+Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor loadInternational Journal of Cancer, 2005